TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: AMBALALSA · data 2026-11-01
Ambalal Sarabhai Enterprises Limited
In plain words
Price: 30.0% below its 52-week high of ₹49.98.
Delivery: 53.5% of traded shares were kept for delivery over the last 10 sessions, against 62.5% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹206 cr |
| Net profit (last 12 months) | ₹14 cr |
| Sales growth, 3 years (yearly) | 5.9% |
| Profit growth, 3 years (yearly) | 15.9% |
At a glance
P/E 19.8, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 11.9%, ROCE 9.4%, operating margin 5.1%: how much profit it earns on the money it uses.
Debt/equity 0.36, Profit growth 15.9% and sales growth 5.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 15.9% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Ambalal Sarabhai Enterprises Limited debt-free?
Its latest reported debt-to-equity ratio is 0.36.
What is Ambalal Sarabhai Enterprises Limited's P/E ratio?
About 19.8, based on the last 12 months' earnings and a price of ₹34.99 (data 2026-11-01).
What is the 52-week high and low of Ambalal Sarabhai Enterprises Limited?
The 52-week high is ₹49.98 and the 52-week low is ₹30.15.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Ambalal Sarabhai Enterprises Limited | ₹34.99 | ₹268 cr | 19.8 | — | 11.9% | 9.4% | 0.36 | +8.3% |
| Jenburkt Pharmaceuticals Ltd | ₹863.1 | ₹377 cr | 11.6 | — | 18.8% | 22.7% | 0.01 | -17.2% |
| Medicamen Biotech Limited | ₹256.9 | ₹347 cr | 31.4 | — | 3.9% | 5.5% | 0.18 | -29.4% |
| Aarey Drugs & Pharmaceuticals Ltd. | ₹106.43 | ₹298 cr | 72.6 | — | 2.7% | 6% | 0.33 | +16.1% |
| Accretion Pharmaceuticals Ltd. | ₹199.55 | ₹211 cr | 22.9 | 4.1 | 27.6% | 38.3% | 0.23 | +242.6% |
| Nectar Lifesciences Ltd. | ₹10.3 | ₹200 cr | — | — | -7.5% | -0.9% | 0 | -31.8% |
Compare AMBALALSA with JENBURPH in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AMBALALSA in TickerKhoj →